2-((2,6-dichlorophenyl)amino) benzeneacetic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl ester

a hydrogen sulfide-releasing compound; structure in first source

Also Known As:

ACS15

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylacetates: 3
      - Diclofenac: 4384
        2-((2,6-dichlorophenyl)amino) benzeneacetic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl ester: 2
- Sulfur Compounds: 278
  - Thiones: 70
    - 2-((2,6-dichlorophenyl)amino) benzeneacetic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl ester: 2
Inorganic Chemicals: 9
- Thiones: 70
  - 2-((2,6-dichlorophenyl)amino) benzeneacetic acid 4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl ester: 2

Experts

1.	Del Soldato, P: 1 article (03/2012)
2.	Frantzias, J: 1 article (03/2012)
3.	Idris, A I: 1 article (03/2012)
4.	Logan, J G: 1 article (03/2012)
5.	Mollat, P: 1 article (03/2012)
6.	Ralston, S H: 1 article (03/2012)
7.	Sparatore, A: 1 article (03/2012)
8.	Bhatia, Madhav: 1 article (01/2008)
9.	Moore, Philip K: 1 article (01/2008)
10.	Sidhapuriwala, Jenab N: 1 article (01/2008)

Related Diseases

1.	Lung Injury 01/01/2008 - "Diclofenac and ACS15 were administered either 1 hour before or 1 hour after starting cerulein injections, and the severity of acute pancreatitis and associated lung injury was assessed. "
2.	Pneumonia (Pneumonitis) 01/01/2008 - "ACS15, given prophylactically and therapeutically, significantly reduced lung inflammation without having any significant effect on pancreatic injury. "
3.	Pancreatitis 01/01/2008 - "Diclofenac and ACS15 were administered either 1 hour before or 1 hour after starting cerulein injections, and the severity of acute pancreatitis and associated lung injury was assessed. "
4.	Osteolysis 03/01/2012 - "In calvaria organ culture, human MDA-MB-231 cells caused osteolysis, and this effect was completely prevented following treatment with ACS15 and ACS32. " 03/01/2012 - "We studied the effects of the S-DCF derivatives ACS15 and ACS32 on osteoclast and osteoblast differentiation and activity in vitro, human and mouse breast cancer cells support for osteoclast formation and signalling in vitro, and osteolysis ex vivo. "
5.	Breast Neoplasms (Breast Cancer) 03/01/2012 - "We studied the effects of the S-DCF derivatives ACS15 and ACS32 on osteoclast and osteoblast differentiation and activity in vitro, human and mouse breast cancer cells support for osteoclast formation and signalling in vitro, and osteolysis ex vivo. " 03/01/2012 - "The S-diclofenac derivatives ACS15 and ACS32 inhibited the increase in osteoclast formation induced by human MDA-MB-231 and MCF-7 and mouse 4T1 breast cancer cells without affecting breast cancer cell viability. "

Related Drugs and Biologics

1.	Diclofenac (SR 38)
2.	Ceruletide
3.	(3- (2,6- dichloro- phenylamino)phenyl)acetic acid 2-methanesulphonylsulphanyl ethyl ester
4.	2- ((2,6- dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester

Related Therapies and Procedures

1.	Injections